Novartis India Ltd
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare BSE Allcap
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Figures in Rs. Crores
| Net Cash Flow |
| Free Cash Flow |
| CFO/OP |
Ratios
Figures in Rs. Crores
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Permanent Employees Count ・Standalone data |
|
||||||||||
| Number of Core Strategic Brands Brands ・Standalone data |
|||||||||||
| Rural Reach - Villages Covered (Arogya Parivar) Villages ・Standalone data |
|||||||||||
| Reach - Healthcare Professionals / Doctors Count ・Standalone data |
|||||||||||
| Distribution Network - Number of Distributors/Dealers Count ・Standalone data |
|||||||||||
| Market Share - Transplant Induction Patients Percentage ・Standalone data |
|||||||||||
Documents
Announcements
-
Board Meeting Intimation for Intimation Of Meeting Of The Board Of Novartis India Limited ('The Company') And Closure Of Trading Window.
31 Mar - Board meeting May 12, 2026 to approve audited results for year ended Mar 31, 2026; trading window closed Apr 1. --- Checklist: - Identify regulatory …
- Closure of Trading Window 31 Mar
-
Intimation Of The Receipt Of Delhi High Court Order Admitting Company Petition In The Matter Of Novartis India Limited Vs. Commissioner Of Trade And Taxes (W.P.(C) 3892/2026)
30 Mar - Delhi High Court admitted petition challenging DVAT demand ~INR10.89 crore and penalty ~INR6.85 crore (petition received March 29, 2026)
-
Intimation Under Reg 30 Of SEBI LODR Of Receipt Of TDS Order As Per Income Tax Act
27 Mar - Notice (26 Mar) and order (27 Mar 2026) for INR 10.28 crore TDS demand; appeal and stay planned.
-
Announcement under Regulation 30 (LODR)-Change in Management
27 Mar - Appoint Gowree Gokhale as Independent Director from April 1, 2026 (5-year term); Sandra Martyres exits April 18, 2026; postal ballot.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business
The company is primarily engaged in the pharmaceutical business in the area of pain management, organ transplantation, neuroscience, etc. [1]